BridgeMD
New treatment option for Ischemic Stroke, Acute
Official title Effects of Transcranial Magnetic Stimulation After Endovascular Treatment for Acute Ischemic Stroke
ClinicalTrials.gov ID: NCT06639360
What this study is testing
- What it's testing
- This is a multicenter, randomized, double-blind, sham-controlled trial, to determine the efficacy and safety of cTBS in treating patients with acute ischemic stroke after endovascular treatment.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Patients with acute anterior circulation ischemic stroke aged between 18 and 80 years old.
- Imaging suggests that the infarction is caused by occlusion of the terminal portion of the internal carotid artery or the M1/M2 segment of the middle...
- A head CT within 24 hours of onset indicates an ASPECT score ≥6, and meets the guideline-recommended criteria for thrombectomy.
- Pre-stroke mRS score is ≤1.
- NIHSS score before thrombectomy is between 6 and 25.
You likely can't join if
- Patients with contraindications to TMS treatment, such as those with metallic foreign objects in the head, pacemakers, implantable drug pumps...
- Patients with epilepsy, increased intracranial pressure, tumors, acute cerebral hemorrhage, or other severe neurological diseases, and those with...
- Head CT/MRI indicates midline shift or significant mass effect, or patients planned for surgical intervention;
- Head CT/MRI suggests acute cerebral infarction in both sides;
- Patients who are pregnant or breastfeeding;
- Patients with severe mental disorders or dementia who cannot cooperate with follow-up;
See the full eligibility criteria
- Patients with acute anterior circulation ischemic stroke aged between 18 and 80 years old.
- Imaging suggests that the infarction is caused by occlusion of the terminal portion of the internal carotid artery or the M1/M2 segment of the middle cerebral artery.
- A head CT within 24 hours of onset indicates an ASPECT score ≥6, and meets the guideline-recommended criteria for thrombectomy.
- Pre-stroke mRS score is ≤1.
- NIHSS score before thrombectomy is between 6 and 25.
- With vascular recanalization of mTICI \> 2b/3.
- Informed consent form signed.
- Patients with contraindications to TMS treatment, such as those with metallic foreign objects in the head, pacemakers, implantable drug pumps, cochlear implants, etc.;
- Patients with epilepsy, increased intracranial pressure, tumors, acute cerebral hemorrhage, or other severe neurological diseases, and those with severe functional impairment of organs such as the heart, liver, and...
- Head CT/MRI indicates midline shift or significant mass effect, or patients planned for surgical intervention;
- Head CT/MRI suggests acute cerebral infarction in both sides;
- Patients who are pregnant or breastfeeding;
- Patients with severe mental disorders or dementia who cannot cooperate with follow-up;
- Patients with other severe diseases resulting in an expected survival of less than 90 days;
- Patients who are participating in other treatment clinical studies within 30 days before the start of this study or after the onset of this condition;
- Patients who cannot cooperate with informed consent.
The study team makes the final eligibility decision.
Where it's taking place
- Xi'an, Shaanxi, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Xi'an, Shaanxi, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.